Romiplostim is a second-generation thrombopoietin receptor (TPO-R) agonist and the first FDA-approved thrombopoietic agent for the treatment of immune thrombocytopenia (ITP). It mimics endogenous thrombopoietin to stimulate platelet production, aiming to increase and maintain platelet counts at a safe level, thereby reducing the risk of bleeding and alleviating symptoms in both adult and pediatric ITP patients. It is administered as a once-weekly subcutaneous injection and is indicated for long-term use in patients with chronic ITP who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy.